These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3926333)

  • 21. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.
    Jordan VC; Fritz NF; Langan-Fahey S; Thompson M; Tormey DC
    J Natl Cancer Inst; 1991 Oct; 83(20):1488-91. PubMed ID: 1920495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steroid sex hormones and prolactin in postmenopausal women with generalized mammary carcinoma during prolonged dexamethasone treatment.
    Borkowski A; L'hermite M; Dor P; Longeval E; Rozencweig M; Muquardt C; Van Cauter E
    J Endocrinol; 1977 May; 73(2):235-46. PubMed ID: 140915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
    Klijn JG; de Jong FH
    Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acne conglobata responding to buserelin, a gonadotrophin-releasing hormone analogue.
    Waxman J; Rustin MH; Perry L; Kirby JD
    Br J Dermatol; 1983 Dec; 109(6):679-81. PubMed ID: 6228245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gn-RH agonists in breast and gynaecologic cancer treatment.
    Nicholson RI; Walker KJ
    J Steroid Biochem; 1989 Oct; 33(4B):801-4. PubMed ID: 2532269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
    Lockwood GM; Pinkerton SM; Barlow DH
    Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
    Cassano A; Astone A; Garufi C; Noviello MR; Pietrantonio F; Barone C
    Cancer Lett; 1989 Nov; 48(2):123-4. PubMed ID: 2555044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The first clinical use of depot buserelin for advanced prostatic carcinoma.
    Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
    Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
    Ferrari V; Zaniboni A; Simoncini E; Marpicati E; Montini E; Moretti R; Marini G
    Chemioterapia; 1988 Dec; 7(6):414-9. PubMed ID: 3146444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zoladex: therapeutic effects in postmenopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH; Wenderoth UK; Ehrenthal W; von Wallenberg H; Spindler HW; Hohenfellner R
    Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of pituitary-gonadal suppression with a gonadotrophin-releasing hormone agonist on fetal gonadotrophin secretion, fetal gonadal development and maternal steroid secretion in the sheep.
    Thomas GB; McNeilly AS; Gibson F; Brooks AN
    J Endocrinol; 1994 May; 141(2):317-24. PubMed ID: 8046302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of endometriosis with gonadotropin releasing hormone agonist (buserelin).
    Sirimongkolkasem R; Rojanasakul A; Chailurkit LO
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():37-41. PubMed ID: 2112582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
    Robertson JF; Walker KJ; Nicholson RI; Blamey RW
    Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.